News
Elastagen Strengthens Board with Appointment of Xavier Yon
December 2011, Sydney: Elastagen, a clinical stage medical device company that is pioneering Elastatherapy™ using the human protein Elastin to naturally repair and augment the skin, is pleased to announce the appointment of Xavier Yon to its Board, as a Non-Executive Director.
Elastagen Featured in Prime Magazine
October 2011, Sydney: In an industry as fast-paced as aesthetic medicine and dermatology, perhaps it was only a matter of time until a product was developed to rival the botulinum toxins and hyaluronic acids.
Elastagen Expands Clinical Program for Elastin Products
September 2011, Sydney: Following the successful conclusion of its first-in-man study conducted earlier this year, Elastagen has expanded its clinical program to assess the safety and efficacy of its Elastin products in the augmentation and repair of aged and damaged skin.
Elastagen Initiates Clinical Testing of Elastin Products
December 2010, Sydney: Elastagen has passed another key milestone in its development having enrolled and implanted the first patient in its first–in-man clinical study to evaluate the safety of its Elastin products for the augmentation and repair of aged and damaged skin.
Skin Elastin Products A Significant Step Closer
December 2009, Sydney: The past year has seen Elastagen put in place the key technology and commercial platforms which will enable the Company to launch formal development of its novel Elastin products to treat aged and damaged skin.
Elastagen Secures Financing and Appoints Management Team
December 2008, Sydney: For Elastagen, 2008 has been a pivotal year in the Company’s development. In August of this year, Elastagen raised AU$5 million investment in the next phase of development of its breakthrough non-surgical anti-ageing treatments. The Company has also successfully attracted an experienced management team and Board of Directors to drive its future development.
Latest News
What the Experts Say
| Feb ’11 | The Science of Elastin |